BioSpace News Archive

ImmunoForge Expands Drug Development Licensing Agreement with Duke University

ImmunoForge has announced on the 18th that it has expanded its license rights with Duke University to enhance joint research and drug development opportunities in relation to the elastin-like polypeptide platform technology.

May 18, 2023
·
3 min read
Creative Medical Technology Holdings Announces Positive Top-Line Study Results for Chronic Lower Back Pain Utilizing its StemSpine® Procedure Using AlloStem™ Allogenic Cell Line

Creative Medical Technology Holdings, Inc. (“Creative Medical Technology” or the “Company”) (NASDAQ: CELZ) today announced positive top line pilot study results for the StemSpine® procedure using AlloStem™ to treat chronic lower back pain.

May 18, 2023
·
3 min read
Biotech Bay

SiteOne Therapeutics Awarded up to $15M Grant to Develop NaV1.8 Inhibitor as Non-Opioid Therapeutic for Pain

SiteOne Therapeutics, Inc. today announced that it has received a grant (UG3DA058552) for up to $15 million from the National Institute on Drug Abuse (NIDA) for the development of STC-004, an investigational, non-opioid treatment for acute and chronic pain conditions.

May 18, 2023
·
4 min read
Pharm Country

Kapruvia® (difelikefalin) recommended by England’s NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus

Vifor Fresenius Medical Care Renal Pharma and Cara Therapeutics, Inc. announced that England’s National Institute for Health and Care Excellence has recommended Kapruvia® for the treatment of moderate-to-severe CKD-associated pruritus in adult patients on haemodialysis.

May 18, 2023
·
5 min read
Asieris Deepens Strategic Partnership with UroViu to Further Develop Integrated Diagnosis and Treatment Platform for Bladder Cancer

Asieris Pharmaceuticals, a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced a strategic collaboration with UroViu Corporation.

May 18, 2023
·
3 min read
Syngenta Group Moves Forward With Its IPO Plans

Syngenta Group has withdrawn its STAR Market IPO application and will immediately apply for a public listing on the main board at the Shanghai Stock Exchange.

May 18, 2023
·
3 min read
Genetown

Chroma Medicine Presents Data Demonstrating Near-Complete, Durable In Vivo Silencing with Targeted Epigenetic Editors at 2023 ASGCT Annual Meeting

Chroma Medicine, Inc. announced in vivo data that demonstrate 99% silencing of two distinct targets and compelling proof-of-concept for its epigenetic editing platform.

May 18, 2023
·
3 min read
Drug Development

ASLAN Pharmaceuticals Doses First Patient in Phase 2a Trial of Farudodstat in Alopecia Areata

ASLAN Pharmaceuticals today announced that it has dosed the first patient in a Phase 2a proof-of-concept study of farudodstat, an oral dihydroorotate dehydrogenase (DHODH) inhibitor, in adult patients with severe alopecia areata (AA), an autoimmune condition causing hair loss.

May 18, 2023
·
6 min read
Business

Bio-One® names Danessa Itaya president

Bio-One® has named prominent franchise industry leader Danessa Itaya as the company’s new president.

May 18, 2023
·
3 min read
Novartis Canada launches new head office in the Health Innovation District of Montréal, featuring a unique environment to inspire co-creation, partnerships and continued healthcare innovation

Novartis Pharmaceuticals Canada Inc. is pleased to announce the official opening of its new Montréal office in the heart of Old Montréal.

May 18, 2023
·
5 min read